Research & Development in
Bellinzona

Fondazione per l'istituto di Ricerca in Biomedicina (IRB)

Since 1997 · 21–50 empl.·4.7(47)

The company's core activity is research and teaching in the fields of biology, chemistry and related sciences, particularly in the areas of mass spectrometry, microscopy, protein production and animal welfare. The company also provides support services such as IT support, technology transfer, administration and training, including PhD programs, master's and bachelor's theses as well as pre-doctoral training.

Fondazione per la ricerca sul cancro nel Ticino

Since 1985 · 11–20 empl.

Fondazione per la ricerca sul cancro nel Ticino funds scientific research projects in oncology and awards research scholarships and a prize. The foundation operates in coordination with Lega cancro Ticino, which by statute holds the majority of seats on the foundation board and supports the allocation of grants to researchers domiciled or active in the canton.

Tecnomedia Service Sagl

Since 1994 · 1–10 empl.

Tecnomedia Service Sagl provides technical services across visuals, acoustics, mechanics, electronics and information technology. Services include managed video surveillance (design, installation, operation, maintenance and remote access), webcam hosting and architectural acoustic analysis and remediation.

Fondazione Sir John Eccles

Since 2003 · 11–20 empl.

The core activity of the Fondazione Sir John Eccles is to promote scientific and philosophical studies and research in the field of neurobiology, particularly with regard to the relationship between the brain and consciousness. The foundation organizes events, conferences, symposia, and research programs to foster dialogue between scientists, philosophers, and experts from various disciplines. It also supports the publication of research results and the organization of cultural events to inform the public about the latest developments in this field.

Humabs BioMed SA

Since 2011 · 11–20 empl.

The core activity of Humabs BioMed SA is the discovery and development of anti-infective immunotherapies for the treatment of viral and bacterial diseases, including those caused by Zika, Ebola, Rabies, Dengue and other Flaviviruses. The company focuses on the development of therapeutics up to clinical proof of concept and has a broad pipeline of development candidates.

MV BioTherapeutics SA

Since 2018 · 11–20 empl.

The core activity of MV BioTherapeutics SA is the development and application of technologies for regulating the intestinal ecosystem in medical applications, particularly through the ApyraMed/ApyraVax platform. This platform enables the conditional regulation of the intestinal ecosystem to control the adaptive immune response and promote mutualism with intestinal commensals. The company focuses on developing solutions for medical applications, particularly in the fields of mucosal immunology and biomedicine.

Bios plus

Since 2021 · 21–50 empl.

The core activity of Bios⁺ is to promote, support and coordinate scientific research and teaching in the field of life sciences. The goal is to create a national and international research center for life sciences in Bellinzona, Switzerland.

Fondazione per l'Istituto Oncologico di Ricerca (IOR)

Since 1999 · 101–500 empl.·3.8(4)

The company's core activity is medical research and development, particularly in the field of cancer research and treatment. The company is involved in translational and clinical research, development of innovations and technologies, as well as the publication of research results and reports. There are also indications of collaboration with external partners and the application for research funding. The specific research areas include, among others, cancer immunotherapy, experimental hematology, prostate cancer, microbiota and cancer metabolism.

Rotorborne Sagl

Since 2026 · 1–10 empl.

Fondazione per la cura e la ricerca nel campo delle malattie cardiovascolari

Since 1996 · 1–10 empl.

Società ticinese per la ricerca scientifica

Since 2002 · 1–10 empl.

Società cooperativa RicercaStudio

Since 2018 · 1–10 empl.